$2.36
+0.04 (+1.72%)
Open$2.36
Previous Close$2.32
Day High$2.37
Day Low$2.30
52W High$4.00
52W Low$2.03
Volume—
Avg Volume159.5K
Market Cap238.66M
P/E Ratio—
EPS$-0.66
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+907.6% upside
Current
$2.36
$2.36
Target
$23.78
$23.78
$21.93
$23.78 avg
$37.21
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.59M | 3.70M | 119.79M |
| Net Income | -70,707,788 | -65,524,103 | 199.8K |
| Profit Margin | -1,971.7% | -1,873.1% | 0.2% |
| EBITDA | -67,067,226 | -65,603,237 | 316.5K |
| Free Cash Flow | — | — | 248.3K |
| Rev Growth | -2.9% | -2.9% | -0.9% |
| Debt/Equity | 0.10 | 0.10 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |